TY - JOUR
T1 - A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children
AU - Bélard, Sabine
AU - Issifou, Saadou
AU - Hounkpatin, Aurore B
AU - Schaumburg, Frieder
AU - Ngoa, Ulysse Ateba
AU - Esen, Meral
AU - Fendel, Rolf
AU - de Salazar, Pablo Martinez
AU - Mürbeth, Raymund E
AU - Milligan, Paul
AU - Imbault, Nathalie
AU - Imoukhuede, Egeruan Babatunde
AU - Theisen, Michael
AU - Jepsen, Søren
AU - Noor, Ramadhani A
AU - Okech, Brenda
AU - Kremsner, Peter G
AU - Mordmüller, Benjamin
PY - 2011
Y1 - 2011
N2 - GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.
AB - GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.
U2 - 10.1371/journal.pone.0022525
DO - 10.1371/journal.pone.0022525
M3 - Journal article
C2 - 21829466
VL - 6
SP - e22525
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 7
ER -